Inclusion Criteria:

• * Willing and able to provide written informed consent
• * Age \>= 18
• * Documented HIV infection
• * Antiretroviral therapy for at least 12 months
• * Screening plasma HIV RNA levels below level of detection (\< 40-75 copies/mL), and all available determinations in past 12 months also below level of detection (blips allowed)
• * Screening CD4+ T-cell count \>350 cells/uL
• * If of childbearing potential, willing to use two methods of contraception
• * Willing to receive counseling regarding HIV transmission risk mitigation

Exclusion Criteria:

• * Pregnant or plans to become pregnant during the course of the study
• * Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb and positive HBV DNA
• * Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA
• * Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen
• * Significant cardiovascular or cerebrovascular disease
• * Recent or prior (within past 5 years) malignancy
• * Severe kidney disease (CrCl \< 50 mL/min via Cockroft-Gault method)
• * Severe hepatic impairment (Child-Pugh Class C) or unstable liver disease
• * Concurrent treatment with immunomodulatory drugs
• * Unable or unwilling to use barrier protection or pre-exposure prophylaxis (PrEP) to prevent HIV transmission with sexual partners not known to be HIV-infected